Medicine and Dentistry
Small Cell Lung Cancer
100%
Irinotecan
100%
Patient
31%
Adverse Event
25%
Neuroendocrine Carcinoma
18%
Analysis
12%
Neutropenia
12%
Nausea and Vomiting
12%
Diarrhea
12%
Health Care Cost
12%
Infusion
12%
Enterocolitis
6%
Side Effect
6%
Acute Kidney Injury
6%
Cancer of Unknown Primary Origin
6%
Ileus
6%
Bladder
6%
Patient Population
6%
Cancer
6%
Cost Benefit Analysis
6%
Progression Free Survival
6%
Age
6%
Health Care Facility
6%
Clinical Study
6%
Febrile Neutropenia
6%
Diagnosis
6%
Gastroesophageal Junction
6%
Cost-Effectiveness Analysis
6%
Malignant Neoplasm
6%
Therapeutic Procedure
6%
Elevated Transaminases
6%
Financial Toxicity
6%
Pharmacology, Toxicology and Pharmaceutical Science
Irinotecan
50%
Small Cell Lung Cancer
50%
Adverse Event
25%
Neuroendocrine Carcinoma
18%
Diarrhea
12%
Nausea and Vomiting
12%
Neutropenia
12%
Malignant Neoplasm
6%
Cancer of Unknown Primary Site
6%
Acute Kidney Failure
6%
Progression Free Survival
6%
Enterocolitis
6%
Toxicity
6%
Clinical Study
6%
Hypertransaminasemia
6%
Side Effect
6%
Ileus
6%
Febrile Neutropenia
6%
